Overcoming barriers by local drug delivery with liposomes

被引:201
|
作者
Antimisiaris, S. G. [1 ,2 ]
Marazioti, A. [1 ]
Kannavou, M. [1 ,2 ]
Natsaridis, E. [1 ,2 ]
Gkartziou, F. [2 ]
Kogkos, G. [1 ,2 ]
Mourtas, S. [1 ]
机构
[1] Univ Patras, Sch Hlth Sci, Dept Pharm, Lab Pharmaceut Technol, Rion 26504, Greece
[2] Fdn Res & Technol Hellas FORTH ICES, Inst Chem Engn Sci, Rion 26504, Greece
关键词
Liposomes; Drug; Topical routes; Local delivery; Administration; Ocular; Pulmonary; Nasal; Oral; Intratumoral; Vaginal; Vaccine; COVID-19; BLOOD-BRAIN-BARRIER; SURFACE-MODIFIED LIPOSOMES; IN-VITRO CHARACTERIZATION; SUSTAINED-RELEASE; TRANSDERMAL DELIVERY; CATIONIC LIPOSOMES; LOADED LIPOSOMES; OCULAR DELIVERY; DRY POWDER; BIOLOGICAL BARRIERS;
D O I
10.1016/j.addr.2021.01.019
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Localized or topical administration of drugs may be considered as a potential approach for overcoming the problems caused by the various biological barriers encountered in drug delivery. The combination of using localized administration routes and delivering drugs in nanoparticulate formulations, such as liposomes, may have additional advantages. Such advantages include prolonged retention of high drug loads at the site of action and controlled release of the drug, ensuring prolonged therapeutic effect; decreased potential for side-effects and toxicity (due to the high topical concentrations of drugs); and increased protection of drugs from possible harsh environments at the site of action. The use of targeted liposomal formulations may further potentiate any acquired therapeutic advantages. In this review we present the most advanced cases of localized delivery of liposomal formulations of drugs, which have been investigated pre-clinically and clinically in the last ten years, together with the reported therapeutic advantages, in each case. (c) 2021 Elsevier B.V. All rights reserved.
引用
收藏
页码:53 / 86
页数:34
相关论文
共 50 条
  • [31] Liposomes as drug delivery systems
    Clark, AP
    CANCER PRACTICE, 1998, 6 (04) : 251 - 253
  • [32] Liposomes - Opportunities in drug delivery
    Allen, TM
    DRUGS, 1997, 54 (Suppl 4) : 8 - 14
  • [33] LIPOSOMES FOR THE DRUG DELIVERY OF CARBORANES
    Olusanya, Temidayo
    NEURO-ONCOLOGY, 2013, 15 : 61 - 61
  • [34] Liposomes for drug delivery in stroke
    Bruch, Gisele E.
    Fernandes, Lorena F.
    Bassi, Beatriz L. T.
    Alves, Marco Tullio R.
    Pereira, Isabelle O.
    Frezard, Frederic
    Massensini, Andre R.
    BRAIN RESEARCH BULLETIN, 2019, 152 : 246 - 256
  • [35] DRUG DELIVERY USING LIPOSOMES
    ASSERAF, P
    GAZETTE MEDICALE, 1990, 97 (28): : 11 - 15
  • [36] Characterizing Liposomes for Drug Delivery
    Carnell, Pauline
    Kaszuba, Mike
    R&D MAGAZINE, 2014, 56 (02): : 16 - 17
  • [37] Overcoming negatively charged tissue barriers: Drug delivery using cationic peptides and proteins
    Vedadghavami, Armin
    Zhang, Chenzhen
    Bajpayee, Ambika G.
    NANO TODAY, 2020, 34 (34)
  • [38] Antibody-Based Formats to Target Glioblastoma: Overcoming Barriers to Protein Drug Delivery
    Ghosh, Saikat
    Huda, Pie
    Fletcher, Nicholas L.
    Howard, Christopher B.
    Walsh, Bradley
    Campbell, Douglas
    Pinkham, Mark B.
    Thurecht, Kristofer J.
    MOLECULAR PHARMACEUTICS, 2022, 19 (05) : 1233 - 1247
  • [39] LIPOSOMES IN TOPICAL DRUG DELIVERY
    SCHAEFFER, HE
    KROHN, DL
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 1982, 22 (02) : 220 - 227
  • [40] LIPOSOMES AS A DRUG DELIVERY SYSTEM
    JULIANO, RL
    TRENDS IN PHARMACOLOGICAL SCIENCES, 1981, 2 (02) : 39 - 42